How does nk cell therapy work

Overview

Natural killer (NK) cell therapy represents a significant advancement in cancer immunotherapy, building upon decades of immunological research. NK cells were first identified in the 1970s by Rolf Kiessling and colleagues as lymphocytes capable of killing tumor cells without prior sensitization. Unlike T-cells which require antigen presentation via MHC molecules, NK cells employ a "missing self" recognition system where they attack cells lacking proper MHC class I molecules - a common feature of cancer and virus-infected cells. Historically, NK cell research gained momentum in the 1990s with the discovery of activating and inhibitory receptors that regulate their function. The field accelerated in the 2010s with the development of techniques to expand NK cells ex vivo for therapeutic use. By 2020, over 100 clinical trials were investigating NK cell therapies for various cancers, with particular focus on hematological malignancies where they've shown the most promise. The technology has evolved from using donor-derived NK cells to developing off-the-shelf products and genetically engineered CAR-NK cells.

How It Works

NK cell therapy functions through a multi-step process beginning with NK cell collection, typically from peripheral blood, umbilical cord blood, or induced pluripotent stem cells. These cells are then expanded and activated ex vivo using cytokines like IL-2, IL-15, or IL-21, increasing their numbers 100-1000 fold over 2-3 weeks. The activated NK cells recognize target cells through a balance of activating receptors (such as NKG2D, DNAM-1, and natural cytotoxicity receptors) and inhibitory receptors (like KIRs and CD94/NKG2A). When activating signals dominate, NK cells form immunological synapses with target cells and release perforin and granzymes within minutes, creating pores in target cell membranes and inducing apoptosis. Alternatively, they can trigger death receptors like Fas on target cells. Some advanced approaches involve genetic engineering to create CAR-NK cells that express chimeric antigen receptors targeting specific tumor antigens, enhancing specificity. After infusion, these cells circulate, identify abnormal cells, and initiate killing while potentially recruiting other immune components through cytokine secretion.

Why It Matters

NK cell therapy matters because it addresses critical limitations of existing cancer treatments. Unlike chemotherapy which damages healthy cells, NK cells specifically target abnormal cells, potentially reducing side effects. Compared to CAR-T cell therapies, NK cell therapies offer several advantages: they don't require HLA matching (enabling off-the-shelf products), have lower risk of cytokine release syndrome and neurotoxicity, and can kill cancer cells through multiple mechanisms. This makes them particularly valuable for patients who relapse after conventional treatments or who aren't candidates for CAR-T therapy. Beyond oncology, NK cell therapies show promise for treating viral infections (like CMV and EBV) and autoimmune conditions. The approval of the first NK cell therapy in 2023 marked a milestone in making these treatments more accessible, potentially transforming care for blood cancers and paving the way for solid tumor applications.